Skip to main content
Premium Trial:

Request an Annual Quote

Acquisitive Invitrogen is at it Again

NEW YORK, May 25 (GenomeWeb News) - Invitrogen, with two acquisitions already under its belt this year, has done it again.

The Carlsbad, Calif.-based company has purchased the assets of microarray maker Xeotron of Houston, Texas, for an undisclosed sum, the company confirmed today.

Invitrogen is an aggregator of life science companies that produce and sell reagents and tools, and is armed with some $890 million in cash and investments.

The purchase follows the  April purchase of protein microarray maker Protometrix of Branford, Conn., also for an undisclosed sum, and the $403 million purchase in  February of BioReliance, a Rockville, Md.-based contract service organization.

For details, see 
BioArray News.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.